Ever since we launched our GLOW Bioidentical Hormone Replacement Therapy (BHRT) program I’ve been getting a ton of questions from women who are intrigued, curious, and confused about hormone replacement therapy. They know they want the benefits that hormone replacement can provide, but they are still on the fence… wondering if it’s right for them. So, I decided to answer the most common questions here, since it’s possible you are looking for answers as well.
The exciting news is that in just the past few months, we have helped hundreds of women regain healthy hormonal balance, reverse age-related symptoms, and protect themselves from diseases such as osteoporosis, dementia, heart disease, diabetes, and cancer… by addressing the key underlying deficiencies in their hormones.
This article is designed to help you explore the process of natural hormone replacement and decide whether bioidentical hormones and natural hormone replacement therapy are appropriate for you.
WHAT ARE BIOIDENTICAL HORMONES?
Bioidentical hormones are natural hormones that have an identical chemical and molecular structure as hormones produced by the human body. When we refer to bioidentical hormone replacement we are mainly talking about the steroid hormones that include bioidentical estrogen, bioidentical progesterone, bioidentical testosterone, and bioidentical DHEA.
Bioidentical hormones have the same molecular structure as the human body’s natural hormones, therefore both endogenously produced hormones and bioidentical hormones have the same biological action. Bioidentical hormones generate normal, physiological responses from the human body when replaced in the doses required by the body.
Many organs of the human body have receptors for specific hormones. Bioidentical hormones can attach easily to those receptors. Bioidentical hormones, just like human hormones, fit perfectly into the receptors “like a key into a lock”.
Synthetic hormones do not provide an exact fit for the receptor. Due to the fact that they are molecularly different from human hormones. Synthetic hormones can distort the receptor and create damage to that receptor, including damage to the DNA. This can result in numerous side effects such as a stroke and various cancers that are often associated with the use of synthetic hormones.
WHAT ARE THE RAW MATERIALS THAT BIOIDENTICAL HORMONES ARE MADE FROM?
Bioidentical hormones are produced using raw materials that are derived from plants such as wild yam and soy. Wild yam and soy have an abundance of precursor molecules known as “phytohormones” that can be easily converted into bioidentical hormones such as estrogen, progesterone, DHEA, testosterone, etc. However, although bioidentical hormones originate from plant sources, these plant ingredients have been transformed into molecules of bioidentical hormones, therefore bioidentical hormones are not plant extracts.
At GLOW Natural Wellness, we only use wild yam-based hormones.
HOW ARE BIOIDENTICAL HORMONE MANUFACTURED?
The raw material for bioidentical hormones is United States Pharmacopoeia approved for use in bioidentical hormone preparation. The hormones will list the letters “USP” in front of the hormone name at the ingredient level. A facility that has been approved by State Boards and the FDA is obligated to use only those official raw materials that have certificates of analysis as being appropriate for the production of bioidentical hormones.
All of the hormones that we use here at Glow Natural Wellness are made in an FDA-approved and Kosher and GMP-certified facility. The base of our topical hormone creams is Paraben-Free, Soy-Free, Fragrance-Free, Allergen-Free, and EDTA-Free. Our hormones come from organic wild yam extract and are converted into USP progesterone, estradiol, estriol, and DHEA (meeting the standards of the United States Pharmacopeia for strength, purity, and quality
BENEFITS OF BIOIDENTICAL HORMONES
Bioidentical hormones, when dosed and delivered appropriately through bioidentical hormone replacement therapy, re-establishes hormonal balance in the body in a natural way. They follow the same metabolic pathways as the body’s own hormones. Because of their structure – identical to the body’s hormones – bioidentical hormones and bioidentical hormone replacement therapy do not cause the unpleasant and dangerous side effects that synthetic or horse-derived hormones do. Bioidentical hormones will alleviate symptoms of menopause and perimenopause. This means you get your life back! BHRT provides freedom from hot flashes, night sweats, insomnia, low libido, vaginal dryness, hair loss, belly fat, rapid aging, joint pain, and more. For younger, premenopausal women, suffering from irregular menstrual cycles, uterine fibroids, and PMS, bioidentical hormones can balance their menstrual cycle and ease their symptoms.
More importantly, bioidentical hormones have many health-protective benefits such as:
- Preventing osteoporosis, improving bone density and preventing tooth loss.
- Maintaining muscle mass, preventing sarcopenia.
- Helping maintain proper body mass and reducing obesity.
- Improving lipids and cholesterol levels.
- Preserving cardiovascular function, reducing risk of heart disease.
- Protecting youthful brain function, preventing Alzheimers and dementia.
- Balancing mood, reducing anxiety, irritability, and depression.
- Restoring libido and sexual pleasure.
- Improving quality of sleep.
- Enhancing energy.
- Preventing UTI’s and incontinence.
GOALS OF BIOIDENTICAL HORMONE REPLACEMENT THERAPY (BHRT)
The goal of hormone replacement therapy (HRT) using synthetic hormones was to only alleviate menopausal symptoms. The goals of bioidentical hormone replacement therapy (BHRT) are not only to ease unpleasant symptoms of menopause and perimenopause but more importantly to restore youthful hormone balance as well as provide the body with the same protective health benefits that the body’s own natural hormones would provide; in other words, reducing the risk of nearly all age-related disease and extending longevity. This can be accomplished through optimization and balancing of bioidentical hormone levels in a safe, natural way.
WHO NEEDS BIOIDENTICAL HORMONE REPLACEMENT THERAPY?
Bioidentical Hormone Replacement Therapy (BHRT) is beneficial for all who have hormonal imbalances or insufficiencies. Hormonal imbalances can occur at any age and can affect both men and women. Hormonal imbalances can manifest themselves as menopause, perimenopause, PMS, infertility, ovarian cysts, breast cystic lesions, uterine fibroids, polycystic ovarian syndrome (PCOS), adrenal dysfunction, osteoporosis, fibromyalgia, brain fog, and more.
WHEN DO YOU NEED BIOIDENTICAL HORMONE REPLACEMENT THERAPY?
Whenever a hormonal imbalance is diagnosed it can be treated using bioidentical hormones. Unfortunately, allopathic physicians address only the obviously significant abnormalities and typically turn to pharmaceutical drugs to suppress symptoms rather than addressing the source, which is why many hormonal imbalances are undiagnosed and untreated. Midlife women are too often told that their symptoms are just part of “getting older” and offered antidepressants or birth control pills which are of little help. Addressing hormonal imbalances with bioidentical hormone replacement therapy can significantly improve the quality of life and well-being for these women at the present and for years to come.
BIOIDENTICAL HORMONE REPLACEMENT THERAPY DURING REPRODUCTIVE YEARS
Hormonal imbalances during reproductive years can result in menstrual cycle abnormalities such as amenorrhea (lack of menstrual period), menorrhagia (very heavy menstrual bleeding), and dysmenorrhea (painful menstruation). Hormonal imbalances can affect your mood in a negative way, causing premenstrual syndrome (PMS). Uterine fibroids can grow as a result of abnormal estrogen and progesterone levels. Hormonal imbalance and especially low progesterone levels can significantly affect female fertility.
Female athletes may have menstruation problems related to extensive physical training. This can result in amenorrhea, hormonal imbalances, decreased bone density, infertility, and adrenal fatigue, or other forms of adrenal dysfunction. Overtraining and intense physical competition creates increased stress levels and amplifies the production of cortisol at the expense of sex hormones (estrogen, progesterone, and testosterone). Diets that are rich in refined carbohydrates (simple sugars) and without adequate protein intake can also contribute to menstrual disorders.
In addition to lifestyle modifications, bioidentical hormones can be useful to help bring the body back into balance and restore a healthy menstrual cycle.
BIOIDENTICAL HORMONES AND HORMONE REPLACEMENT THERAPY AT PERIMENOPAUSE
Perimenopause is the time period (usually of several years) that precedes menopause. Perimenopause can last anywhere from two years to eight years. The first year after the end of menstruating is also included in perimenopause. During perimenopause the levels of estrogen can fluctuate, menstrual cycles can be shorter or longer, and menstrual periods become irregular. Symptoms of perimenopause are the same as symptoms of menopause and can include hot flashes, night sweats, sleep disturbances, mood swings, and decreased libido. Hormonal fluctuations during perimenopause create perimenopausal symptoms. Bioidentical hormones used by means of bioidentical hormone replacement therapy during perimenopause will restore hormonal balance and improve perimenopausal symptoms.
BIOIDENTICAL HORMONE REPLACEMENT THERAPY DURING AND AFTER MENOPAUSE
During and after menopause, women seek bioidentical hormone replacement therapy to improve menopausal symptoms of hot flashes, sleep disturbances, mood swings, memory problems, loss of libido, etc. The other very important aspect of bioidentical hormone replacement therapy after menopause is to restore the hormonal balance of the body to natural, youthful levels. Bioidentical hormones offer many important health-protective benefits, such as protecting the cardiovascular system, preventing a decline in brain function, balancing mood, as well as protecting against bone loss and osteoporosis.
BIOIDENTICAL HORMONES AND HORMONE REPLACEMENT THERAPY AFTER A HYSTERECTOMY
Many women undergo surgical menopause through hysterectomy. Having a hysterectomy before menopause usually results in severe menopausal symptoms due to a sudden stop in the production of female hormones such as estrogen and progesterone. Allopathic medicine treats post-hysterectomy menopausal symptoms through synthetic hormone replacement therapy, often combined with antidepressants. Bioidentical hormones and bioidentical hormone replacement therapy can re-establish hormonal balance to the body that was drastically deprived of female hormones. Also, allopathic medicine believes that postmenopausal women who have had a hysterectomy and do not have a uterus, do not require progesterone replacement. Doctors who are well educated in women’s health, bioidentical hormones, and bioidentical hormone replacement therapy, know that progesterone plays a much more important role in a woman’s body than just protection from uterine cancer. Therefore, bioidentical progesterone, as well as bioidentical estrogen, is recommended for women after a hysterectomy.
BIOIDENTICAL HORMONES AND BIOIDENTICAL HORMONE REPLACEMENT THERAPY FOR UTERINE FIBROIDS
Uterine fibroids are noncancerous tumors that grow out of the uterus. They usually occur during childbearing years. Uterine fibroids are quite common and often do not cause any symptoms. When symptomatic, uterine fibroids can cause abnormal heavy and painful menstrual periods, pelvic pain, and frequent urination. The growth of uterine fibroids is influenced by estrogen levels. Uterine fibroids have more estrogen receptors than normal uterine muscle tissue. A family history of uterine fibroids can predispose a woman to uterine fibroids. Also, black women have a higher rate of developing uterine fibroids. As well, obesity is considered a risk factor for developing uterine fibroids. Exposure to xenoestrogens (including pesticides, PCBs, and herbicides) predisposes someone to uterine fibroids and causes increased growth of pre-existing uterine fibroids. Women with uterine fibroids typically have hormonal imbalances that can be improved with lifestyle factors, along with a bioidentical hormone replacement and a hormone detox program. There is usually a long-lasting progesterone deficiency and relatively high estrogen levels in these women.
NATURAL BIOIDENTICAL HORMONE REPLACEMENT THERAPY (BHRT) FOR ENDOMETRIOSIS
Endometriosis is a medical condition in which the endometrial uterine cells are deposited in areas of the body other than the uterus. This misplaced uterine tissue responds to the stimulation of female hormones in the same fashion as the endometrial tissue of the uterus. Exposure to xenoestrogens from pesticides and herbicides worsens symptoms of endometriosis. An imbalanced estrogen to progesterone ratio can aggravate symptoms of endometriosis. Natural bioidentical hormone replacement therapy (BHRT) and the use of bioidentical progesterone inhibit the growth of the uterine lining and improve symptoms of endometriosis.
BIOIDENTICAL HORMONES AND HORMONE REPLACEMENT THERAPY FOR OVARIAN CYSTS
Several hormonal imbalances have been associated with ovarian cysts. These include:
- Thyroid hormone deficiency
- Cortisol deficiency
- High prolactin level
- Imbalanced estrogen to progesterone ratio
Also, a deficiency of essential fatty acids can predispose a woman to ovarian cysts. Restoring hormonal balance through bioidentical hormones and bioidentical hormone replacement therapy decreases the likelihood of developing ovarian cysts.
BIOIDENTICAL HORMONES AND HORMONE REPLACEMENT THERAPY FOR BREAST CYSTS
Breast cysts usually develop when levels of estrogen are relatively high, while progesterone levels are low. This hormonal imbalance causes swelling of the breast cells and stimulates the epithelial cells of the breasts to grow in the form of a cyst. Restoring hormonal balance and improving the estrogen to progesterone ratio by utilizing bioidentical hormones and a hormone detox protocol will restore the natural composition of breast tissue.
BIOIDENTICAL HORMONE REPLACEMENT AFTER BREAST CANCER
While it is widely accepted that synthetic hormones increase the risk of breast and ovarian cancers, the same is not the case for bioidentical hormones.
Many treatments for breast cancer block the estrogen receptor or the androgen conversion of estrogen to reduce the risk of relapse. This results in an imbalance of the cancer survivors’ hormones. Without estrogen, clinical symptoms like hot flashes, sleeplessness, insulin sensitivity, and mood changes can creep up, as well as increased incidence of cardiovascular disease and osteoporosis According to the American Society of Clinical Oncology, the use of estrogen and progesterone bio-identical hormone replacement therapy (BHRT) increased well-being and quality of life for women with breast cancer without increased incidence of cancer. In fact, women receiving topical, physiological doses of BHRT actually had less incidence of recurrence.
BIOIDENTICAL HORMONES AND BIOIDENTICAL HORMONE REPLACEMENT FOR INFERTILITY
Proper hormonal balance is essential for healthy conception and normal fetus development. Both male and female hormonal imbalances can result in infertility or a miscarriage. Bioidentical hormones, by restoring natural hormonal balance to the body, can improve fertility, resulting in a normal healthy pregnancy.
HOW TO BEGIN NATURAL BIOIDENTICAL HORMONE REPLACEMENT THERAPY
The best way to begin bioidentical hormone replacement therapy is by consulting an experienced medical doctor who specializes in bioidentical hormones and is well-versed in the utilization of bioidentical hormone replacement therapy. The next step is obtaining a baseline of the current hormonal levels of your body. Baseline hormonal testing is essential for ensuring the safe and precise application of bioidentical hormone replacement therapy. The body’s hormone levels should be monitored on a regular basis. Until a proper balance of hormones is established, hormonal analysis through laboratory testing should be performed every 4 months. Click here to learn about the GLOW BHRT program.
WHAT IS THE PROPER DOSE OF BIOIDENTICAL HORMONES?
Physicians who prescribe bioidentical hormones should utilize a personalized treatment approach. A healthy hormonal balance can only be accomplished when each person’s individual hormonal needs are addressed. At GLOW Natural Wellness, we determine the dose based on a detailed history and symptom assessment, as well as on hormonal laboratory testing. The dose of bioidentical hormones greatly varies from one person to the other, and each woman will have a unique ratio of hormones that helps her feel her best.
USING BIOIDENTICAL HORMONES AND BIOIDENTICAL HORMONE REPLACEMENT THERAPY
The purpose of using bioidentical hormones through bioidentical hormone replacement therapy is to create a state of natural hormonal balance within the body. Therefore, bioidentical hormones are usually administered in a specific form and at a precise time that will support the body’s natural metabolic pathways and circadian rhythm. Hormones that have an energizing effect on the body such as thyroid hormones, testosterone, estrogens or DHEA are usually administered in the morning. Hormones that have a calming, relaxing effect on the body, such as progesterone or melatonin are recommended to be taken at night.
HOW LONG DOES BIOIDENTICAL HORMONE REPLACEMENT THERAPY LAST?
The length of bioidentical hormone replacement therapy depends on the individual health condition and the type of hormonal imbalance. Synthetic hormones were recommended only to alleviate menopausal symptoms and therefore the length of the therapy was limited to several years after menopause. Many women were stopping synthetic hormone replacement therapy due to the unpleasant side effects. In lieu of synthetic hormones, and due to their many positive health benefits and no dangerous side effects (when appropriately administered and carefully monitored), bioidentical hormones and bioidentical hormone replacement therapy can be taken for a prolonged period of time. Additionally, there is no upper age limit for bioidentical hormone replacement therapy. As I like to say, “You are never too old to grow young”.
CAN I USE BIOIDENTICAL HORMONE REPLACEMENT AFTER AGE 65
The use of hormone replacement therapy after age 65 has been a controversial topic. Some doctors feel that hormone replacement after this age is risky and should be avoided. However, they are basing this opinion on the 2002 Women’s Health Initiative Study that used SYNTHETIC hormones. The study found that the use of synthetic hormones in women over age 65 could increase the risk of cancer. This is because synthetic hormones have serious side effects and should not be used by women of any age.
Bioidentical hormones on the other hand are protective for women over the age of 65 and can prevent bone loss, heart disease, and cognitive decline in addition to treating any vasilmotor symptoms. In fact, the North American Menopause Society recently stated, “age shouldn’t dictate whether or not a woman receives hormone therapy”. So, yes… you absolutely can use bioidentical hormone replacement therapy after age 65 if dosed and delivered appropriately.
WHO CAN PRESCRIBE NATURAL BIOIDENTICAL HORMONES AND BIOIDENTICAL HORMONE REPLACEMENT THERAPY?
Unfortunately, very few doctors have any experience with bioidentical hormones and Bioidentical Hormone Replacement Therapy (BHRT). Allopathic doctors are inexperienced in hormonal testing or prescribing bioidentical hormonal formulas. Many allopathic doctors, including gynecologists and endocrinologists, have very little, if any, training on bioidentical hormones. They tend to lump synthetic (dangerous) hormones together with bioidentical (protective) hormones. To experience the full range of health benefits of bioidentical hormones, you’ll want to work with a knowledgeable doctor who can interpret the hormonal laboratory test values and design a hormone replacement program individually suited and customized for you. Since access to educated hormone doctors is limited and can be hard to access, GLOW Natural Wellness recently launched its online GLOW BHRT program, where you can work directly with female hormone experts and board-certified physician, Dr. Michelle Sands and her team to replace your hormones easily and effectively.
SAFETY OF BIOIDENTICAL HORMONES
The safety of bioidentical hormones is assured by several factors:
- The raw materials come from FDA approved facilities.
- Bioidentical hormone creams are manufactured according to FDA standards of quality in a FDA approved facility.
Furthermore, bioidentical hormones are prescribed by and administered under the care and guidelines of qualified medical doctors. Based on the positive clinical results from thousands of patients treated with bioidentical hormones worldwide, bioidentical hormones should be the preferred and standard method for hormone replacement therapy.
BIOIDENTICAL HORMONES VS. CONGUGATED EQUINE ESTROGEN, PROGESTINS AND SYNTHETIC HORMONES
The major difference between bioidentical hormones and synthetic or equine (horse) hormones is their chemical structure. Due to this fact, there is a difference in how bioidentical hormones and their synthetic counterparts work in the body. There are also many different metabolic pathways for each specific type of hormone. Bioidentical hormones, due to their biological action and metabolic pathways being identical to human hormones offer the best path to hormone replacement therapy. On the other hand, synthetic hormones are basically drugs that cover up menopausal symptoms without restoring hormonal balance. However, while reducing menopausal symptoms of hot flushes, night sweats, irritability, etc., synthetic hormones and horse hormones generate many unpleasant side effects. Because of those side effects, many women stop these types of hormone replacement therapies on their own.
The side effects of synthetic hormones are:
- Water retention
- Breast engorgement and discomfort
- Weight gain
- Gallbladder stones
- Blood clots
According to the Women’s Health Initiative, equine estrogen, especially when combined with synthetic progestins, can significantly increase many health risks including breast cancer, heart attack, strokes, blood clots and death from pulmonary cancer. Synthetic progestin stiffens arteries and reduces arterial blood flow, while natural, bioidentical progesterone relaxes blood vessels, improves blood flow and circulation. Bioidentical progesterone increases REM sleep, however synthetic progestins do not.
HOW YOUR BODY UTILIZES BIOIDENTICAL HORMONES
The body utilizes bioidentical hormones the same way as natural body hormones. Bioidentical hormones, due to their chemical structure being identical to that of natural hormones produced by the human body, follow the same metabolic pathways and attach to the receptor sites without causing changes to the receptor site as synthetic hormones do.
WEIGHT LOSS AND BIOIDENTICAL HORMONES
One of the most common symptoms of a hormonal imbalance is weight gain.
Around the time of menopause, most women gain some weight. The size of this gain and its distribution depend on the type of hormones that are declining and the amount of each declining hormone. The ratio of estrogen to progesterone determines the distribution of weight gain. When estrogen decreases out of proportion to progesterone, testosterone, and DHEA, the weight gain is in the middle section of the body. Cortisol, the hormone released during stress, facilitates increased fat storage in the body and weight gain around the waist. If the estrogen is too high and progesterone too low, the weight accumulates around the hips. Bioidentical hormones through bioidentical hormone replacement therapy are the best options for providing natural hormonal balance. Postmenopausal women using bioidentical hormones replacement therapy have a lower incidence of gaining excess body fat and weight.
CARDIOVASCULAR HEALTH, HEART HEALTH, AND BIOIDENTICAL HORMONES
Estrogen and testosterone have protective effects against cardiovascular disease. Estrogen and testosterone lower bad cholesterol levels (LDL cholesterol) while increasing good cholesterol (HDL cholesterol) levels. Lipids, blood sugar, and insulin levels improve with bioidentical hormone replacement therapy. Bioidentical estrogen and bioidentical DHEA (which converts to testosterone) improve the function of the small blood vessels including coronary arteries. Estrogen and testosterone reduce high blood pressure by vasodilatation (increasing the lumen of the arteries) and by decreasing the viscosity of the blood, estrogen, and testosterone to prevent blood clots.
Synthetic progestins block the estrogen’s protective effects on the health of the cardiovascular system. Synthetic progestins cause spasms of the arteries, increasing blood pressure, while bioidentical progesterone decreases blood pressure. Bioidentical progesterone also has a positive effect on lipid metabolism and cholesterol levels.
BONE DENSITY, BONE HEALTH AND BIOIDENTICAL HORMONES
Osteoporosis, or bone loss, happens to both women and men due to a loss of hormones such as estrogen, progesterone, and testosterone. To protect bone health and prevent osteoporosis, the body requires the proper intake of nutrients such as Calcium, Magnesium, Vitamin D, Vitamin K, Boron, Manganese, and Vitamin C. Physical exercise also helps to maintain optimal bone density.
Hormonal balance is of great importance for healthy bones and osteoporosis prevention. Hormones such as estrogen and testosterone prevent bone tissue loss, and progesterone can assist with the rebuilding of lost bone tissue. Bioidentical hormone replacement therapy is a much better way to treat osteoporosis than synthetic drugs such as bisphosphonates or selective estrogen modulators.
MEMORY PROBLEMS, BRAIN HEALTH AND BIOIDENTICAL HORMONES
Estrogen, testosterone, progesterone, and DHEA have beneficial effects on brain function and memory preservation. These hormones improve cognitive function and increase the ability of learning. Studies show that women who are on bioidentical hormone replacement therapy after menopause have a lower incidence of dementia and Alzheimer’s disease. Additionally, the studies show that the longer an individual continues bioidentical hormone replacement therapy, the lower his/her risk for developing Alzheimer’s disease. Bioidentical hormone replacement therapy stimulates the growth of new brain cells and improves neuronal function. Bioidentical hormones act as a guardian by protecting the function of the neurons and increasing oxygen supply.
DEPRESSION, MOOD SWINGS AND BIOIDENTICAL HORMONES
A healthy hormonal balance is necessary for supporting a stable mood. Estrogen, testosterone, and DHEA stimulate the sympathetic nervous system, which increases alertness. Progesterone has a calming, relaxing effect. Estrogen increases the serotonin and endorphin levels in the body, thus bioidentical estrogen has a positive effect on the mood of a woman. A sudden drop in estrogen levels, as happens postpartum, can lead to a drop in serotonin and create a postpartum depression in women who may already have low serotonin levels. Fluctuating levels of estrogen create symptoms of anxiety, depression, and mood swings. Not only do low levels of estrogen create emotional imbalances, but excessively high levels of estrogen can also cause many symptoms as well. The condition in which estrogen is not balanced by progesterone is called estrogen dominance. A foremost important factor that causes estrogen dominance is exposure to environmental toxins such as pesticides, herbicides, and PCBs. Progesterone helps balance mood by stimulating the parasympathetic nervous system. Bioidentical progesterone relieves symptoms of anxiety, insomnia, irritability, and mood swings. Synthetic progestins do not have the same effect, in fact, they can cause mood disturbances called dysphoria.
STRESS AND BIOIDENTICAL HORMONES
Stress, whether emotional or physical, can affect the production and release of many hormones. During stressful situations, the body releases mainly cortisol, a major hormone that helps the body to cope with stress. At that time, the production of other hormones such as DHEA, testosterone, progesterone, and estrogen decreases. If the stressful situation lasts for a prolonged period of time, adrenal glands can become exhausted and the production of cortisol will diminish. Decreased levels of cortisol will further reduce tolerance of stress and have a negative effect on mood. In the time of stress, the body requires higher levels of hormones and therefore the dosage of bioidentical hormones will have to be adjusted. This is why at GLOW Natural Wellness, our BHRT program includes retesting every quarter and constant contact with our clinical team so we can keep your hormones balanced – no matter what life throws your way.
TYPE 2 DIABETES AND BIOIDENTICAL HORMONES
Hormones such as DHEA, cortisol, testosterone, progesterone, estrogen, and thyroid hormones play important roles in regulating levels of blood sugar and insulin sensitivity. Excessive levels of DHEA, cortisol, testosterone, and progesterone influence an increase in insulin. Also, decreased estrogen and thyroid hormones will raise insulin levels. During menopause, women with elevated insulin levels may have higher testosterone to estrogen ratio which can result in a masculinizing effect on the body.
Estradiol improves insulin sensitivity. Insulin resistance will negatively influence the release of DHEA from the adrenal glands. Bioidentical hormone replacement therapy, when applied under the supervision of an experienced hormone doctor, decreases one’s risk for diabetes.
SKIN HEALTH, SKIN REJUVENATION AND BIOIDENTICAL HORMONES
Skin is one of the organs that has estrogen receptors. When the estrogen levels decline, the skin begins to lose elasticity. Bioidentical estrogen increases collagen production in the skin, it also improves blood supply to the skin as well as the production of hyaluronic acid and therefore makes the skin softer, hydrated, and smoother. Bioidentical estrogen also increases the thickness and firmness of the skin. Bioidentical estriol is often utilized in skin creams since it was shown that bioidentical estriol effectively reduces wrinkles by rejuvenating the skin. Depletion of other hormones such as progesterone, testosterone, and growth hormone has an aging effect on the skin similar to that of estrogen depletion. Since bioidentical hormone replacement can reverse the signs of aging and restore youthful appearances, perhaps that is why some of our practice members call their hormones “youth in a bottle”!
ABOUT THE GLOW BIOIDENTICAL HORMONE REPLACEMENT THERAPY PROGRAM (GLOW BHRT)
When it comes to treating symptoms of hormonal imbalance, at GLOW Natural Wellness we only practice the most natural Bioidentical Hormone Replacement Therapy (BHRT). We provide the cleanest bioidentical hormone creams manufactured in the US at a Kosher-certified, FDA-approved facility. Our hormone creams are allergen-free, Paraben-Free, Soy-Free, BPA-Free, and EDTA-Free. We use only organic wild yam-derived USP hormones – meeting the standards of the United States Pharmacopeia for strength, purity, and quality.
Dr. Michelle Sands and her team of skilled clinicians have helped thousands of women around the world find relief from the effects of hormone imbalance brought on by menopause and perimenopause. And the best part… we bring the doctor’s office to you.
Whether you suffer from fatigue, insomnia, mood swings, hot flashes, night sweats, weight gain, bone loss, rapid aging, or any other menopausal symptoms, you can achieve hormone balance through a customized treatment plan that has been designed specifically for YOU. We start with an intake questionnaire, then test your baseline hormone levels. Dr. Michelle will analyze your symptoms alongside your lab results and then consult with you about the best plan to restore balance. Your hormones will ship to your door and every 4 months we will retest and reevaluate your hormone replacement protocol to get you the very best results.
Don’t settle for “this is what happens when you get older”, and please don’t suffer needlessly through your symptoms another day. You deserve to look and feel amazing now, and to preserve your health for the future.
 Rossouw, Jacques E et al. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.” JAMA 288, 3 (2002): 321-33. doi:10.1001/jama.288.3.321.
 Rossouw, Jacques E et al. “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.” JAMA 288, 3 (2002): 321-33. doi:10.1001/jama.288.3.321.
 Anderson, Garnet L et al. “Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.” JAMA 291, 14 (2004): 1701-12. doi:10.1001/jama.291.14.1701.
 Anderson GL et al. “Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial.” The Lancet Oncology 13, 5 (2012): 476-486. doi:10.1016/s1470-2045(12)70075-x.
 Holmberg, L et al. “HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped.” Lancet 363, 9407 (2004): 453-5. doi:10.1016/S0140-6736(04)15493-7.
 Beral, Valerie, and Million Women Study Collaborators. “Breast cancer and hormone-replacement therapy in the Million Women Study.” Lancet 362, 9382 (2003): 419-27. doi:10.1016/s0140-6736(03)14065-2.
 Anderson GL et al. “Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial.” The Lancet Oncology 13, 5 (2012): 476-486. doi:10.1016/s1470-2045(12)70075-x.
 Robbins, Anthony S, and Christina A Clarke. “Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004.” Journal of Clinical Oncology 25, 23 (2007): 3437-9.
 Holm, Marianne et al. “The Influence of Menopausal Hormone Therapy and Potential Lifestyle Interactions in Female Cancer Development-a Population-Based Prospective Study.” Hormones & Cancer 9, 4 (2018): 254-264. doi:10.1007/s12672-018-0338-5.
 Stute P, L. Wildt and J. Neulen. “The impact of micronized progesterone on breast cancer risk: a systematic review.” Climacteric 21, 2 (2018): 111-122. doi:10.1080/13697137.2017.1421925.
 Davis, Ruth, Pelin Batur and Holly L Thacker. “Risks and effectiveness of compounded bioidentical hormone therapy: a case series.” Journal of Women’s Health (2002) 23, 8 (2014): 642-8.
 Zeng, Zexian et al. “Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.” PloS One 13, 5 (2018): e0197064. doi:10.1371/journal.pone.0197064.
 Holmberg, Lars et al. “Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.” Journal of the National Cancer Institute 100, 7 (2008): 475-82. doi:10.1093/jnci/djn058.
 Antoine C et al. “Safety of hormone therapy after breast cancer: a qualitative systematic review.” Human Reproduction 22, 2 (2007): 616–622. doi:10.1093/humrep/del393.
 Files, Julia, Marcia G Ko and Sandhya Pruthi. “Bioidentical hormone therapy.” Mayo Clinic Proceedings 86, 7 (2011): 673-80. doi:10.4065/mcp.2010.0714.
 Hou, Ningqi et al. “Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density.” Journal of the National Cancer Institute 105, 18 (2013): 1365-72. doi:10.1093/jnci/djt207.
 Cobin, Rhoda H et al. “American Association of Clinical Endocrinologists and American College of Endocrinology Position Sstatement on Menopause-2017 Update.” Endocrine Practice 23, 7 (2017): 869-880.
 Gartlehner, Gerald et al. “Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA 318, 22 (2017): 2234-2249. doi:10.1001/jama.2017.16952.
 International Agency for Research on Cancer. “European Code Against Cancer: 12 Ways to Reduce Your Cancer Risk.” Last modified 2016.
1. Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocrine Reviews 1997; 18(5): 701-715.
2. Turner-Cobb JM, Sephton SE, Koopman C, et al. Social support and salivary cortisol in women with metastatic breast cancer. Psychosom Med 2000; 62(3): 337-345.
3. Sephton SE, Sapolsky RM, Kraemer HC, et al. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000; 92(12): 994-1000.
4. Whitley BR, Palmieri D, twerdi CD, et al. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004; 296(2): 151-62.
5. Yu H Shu XO, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Inter J Ca 2003; 105(1): 92-97.
6. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003; 46 Suppl 1: S55-8.
7. Alkhalaf M, El-Mowafy A, Karam S. Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein. Eur J Ca Prev 2002; 11(5): 481-488.
8. DeLellis K, Ingles S, et al. IGF-1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003; 88: 227-82.
9. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003; 139: 923-929.
10. Drew PD, Chavis JA. Female sex steroids; effects upon microglial cell activation. J of Neuroimmunology 2000; 111(1-2): 77-85.
11. Hermsmeyer RIK, Mishra RG, Pavcnik D, Uchida B. Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004; 24: 955-961.
12. Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003; 46 Suppl 1: S55-8.
13. Kassirer JP. Why should we swallow what these studies say? Advanced Studies in Medicine 2004; 4(8): 397-398.
14. Fournier A, Berrino F, Riboi E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International Union Against Cancer 2005; 114: 448-454.
15. Pawlak KJ, Zhang G, Wiebe JP. Membrane 5 – pregane-3, 20-dione receptors in MCR-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5 P and down regulated by the progesterone metabolites, 3 – dihydroprogesterone and 20 – dihydroprogesterone, with associated changes in cell proliferation and detachment. SBMB 2005; 1-11.
16. Mabjeesh N, Escuin D, Lavallee T, Pribluda V, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3: 363-375.
17. Dimitrakakis C, Jones R, Liu A, & Bondy C. Breast cancer incidene in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004; 11: 531-535.
18. Richer JK, Lange CA, Manning NG, et al. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J of Biol Chem 1998; 273(47): 31317-26. 1
19. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994; 368: 237-239.
20. Felson DT, Cummings SR. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis and Rheumatism 2005; 52(9): 2594-2598.
21. Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J of the National Cancer Institute 2004; 96(24): 1856-1865.
22. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-95. 23. Rea MF. Benefits of breastfeeding and women’s health. Jornal de Pediatria 2004; 80: S142-6.
24. Jernstrom H, Lubinski J, Lynch HT, et al. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Nation Ca Institute 2004; 96: 1094-8.
25. Abou-Dakn M, Sheele M, Strecker JR. Does breat-feeding prevent breast cancer? Zentralblatt fur Gynakologie 2003; 125: 48-52.
26. Short RV. What the breast does for the baby, and what the baby does for the breast. Australian and New Zealand Journal of Obste and Gyne 1994; 34: 262-4.
27. Smigel KL. Breast-feeding linked to decreased cancer risk for mother, child. J of the Nation Ca Inst 1988; 80(17): 1362-3. 2
CARDIOVASCULAR BIOMARKERS, PHYSIOLOGY AND PHARMACOLOGY INCLUDING MODULATION BY GENDER SPECIFIC FACTORS
1. Braunstein JB, Kershner DW, Bray P, et al. Interaction of hemostatic genetics with hormone therapy Chest 2002; 121: 906-920.
2. Kroom UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradoil and oral conjugated estrogens on haemostasis variables. Thrombosis and Haemostasis 1994; 71(4): 420-3.
3. Grancha S, Estelles A, Tormo G, et al. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 1991; 81(4): 516-21.
4. Wright D, Poller L, Thomson JM, et al. The effect of hormone replacement therapy on the age-related rise of factor VIIc, and its activity state Thrombosis Research 1997; 85(6): 455-464.
5. Boudoulas KD, Cooke GE, Roos CM. The polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001; 125(1): 112-115.
6. Bladbjerg EM, Skouby SO, Anderson LF, Jespersen J. Effects of different progestin regimes in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Human Reproduction 2002; 17(12): 3235-41.
7. Psaty BM, Smith NL, Menaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infractions in postmenopausal women. JAMA 2001; 285(7): 906-913.
8. Yaffe K, Kanaya A, Lindquist K, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242.
9. Rodriguez I, Kilborn MJ, Liu XX, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
10. Dubey K, Tofovic S, Jackson E. Cardiovascular pharmacology of estradiol metabolites. Journal of Pharmacology and Experimental Therapeutics 2004; 308: 403-409.
11. Pletcher M, Baron R. Primary prevention of cardiovascular disease in women: new guidelines and emerging strategies. Advanced Studies in Medicine 2005; 5: 412-419.
12. Morrison J, Friedman L, Harlan W, Harlan L, et al. Development of the metabolic syndrome in black and white adolescent girls: a longitudinal assessment. PEDIATRICS 2005; 116: 1178-1182.
13. Steptoe A, Lundwall K, Cropley M. Gender, family structure and cardiovascular activity during the working day and evening. Soc Sci Med. 2000; 50(4): 531-539.
14. Lavoie KL, Miller SB, et al. Anger, negative emotion, and cardiovascular reactivity during interpersonal conflict in women. J Psychosom Res. 2001; 51(3): 503-512.
15. Wise DE, Dewester J. Metabolic syndrome and associated cardiovascular disease risk. Am Acad Fam Physicians 2004: CME Bulletin 3(2): 1-5.
16. Esparza J, Fox C, Harper IT, et al. Daily energy expenditure in Mexican and USA Pima Indians: low physical activity as a possible cause of obesity. Int J Obes Relat Metab Disord 2000; 24(1): 55-59.
17. Yaffe K, Kanaya A, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242.
18. Minshall R, Miyagawa K, Chadwick C, et al. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. The FASEB Journal 1998; 12: 1419-1429. 3
19. Miyagawa K, Rosch J, Stanczyk F, et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nature Medicine 1997; (3); 3: 324-327.
20. Toth PP. C-reactive protein: a new tool for evaluating cardiovascular disease risk.3 Family Practice Recertification 27(4)L 27-39.
21. Jacobsen S, Buch P, Rasmussen J, et al. Most NSAIDS rise risk of death after heart attack. Abstract 1838. American Heart Association Annual Conference . 2005; Dallas, TX.
22. Scarbabin P, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. The Lancet 2003; 362: 428-32.
23. Straczek C, Oger E, Beau Yon de Jonage-Canonico M, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation 2005; 112: 3495-3500.
24. Nash DT. C-Reactive protein: A promising new marker of cardiovascular risk? Consultant 2005; 453-460.
25. Eskandari F, Mistry S, Martinez P, et al. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism Clinical and Experimental 2005; 54: 918-924.
26. Jespersen J, Munkvad S, Gram JB. The fibrinolysis and coagulations systems in ischemic heart disease: risk markers and their relation to metabolic dysfunction of the arterial intima. Don Med Bull 1993; 40( ): 495-502.
27. 13. Hoffman CJ, Miller RH, Lawson WE, et al. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 1989; 14( ): 941-946.
28. 14. Cortellaro M, Boschett C, Cofrnacesco E, et al. The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients; principal results; Arterioscler Thromb 1992; 12( ): 1063-1070.
29. Wright D, Poller L, Thomson JM, et al. The effect of hormone replacement therapy on the age-related rise of factor VIIc, and its activity state. Thrombosis Research 1997; 85(6): 455-464.
30. Boudoulas KD, Cooke GE, Roos CM. The polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001; 125(1): 112-115.
31. Bladbjerg EM, Skouby SO, Andersen LF, Jespersen J. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Human Reproduction 2002; 17(12): 3235-41.
32. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarctions in postmenopausal women JAMA 2001; 285(7): 906-913.
33. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-716.
34. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98( ): 731-733.
35. Van Baal W, Kenemans P, Van der Mooren MJ, et al. Increased C-reactive protein levels during short term hormone replacement therapy in healthy postmenopausal women. Thrombosis and Haemostatsis 1999; 81(6): 925-8. 4
36. Rifai N, Buring JE, I-Min Lee, et al. Is C-Reactive protein specific for vascular disease in women? Annals of Internal Medicine 2002; 136(7): 529-533.
37. Crandall C, Palla S, Reboussin B, et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in the PEPI trial. J Womens Health 2006; 15(1): 14-23.
38. Dubey RK, Tofvic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. JPET 2004; 308: 403-409.
39. Kip KE, Marroquin OC, Shaw LF, et al. Global inflammation predicts cardiovascular risk in women: A report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Am Heart J 2005; 150(5): 900-906.
40. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006; 295(3): 306-313.
41. Patel C, Edgerton L, Flake D. What precautions should we use with statins for women of childbearing age? The Journal of Family Practice 2006; 55(1): 75-77.
42. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243-2252.
43. Rao LV, Pendurthi UR. Tissue factor-factor VIIa signaling. Arterioscler Thromb Vasc Biol 2005 Jan; 25(1): 47-56.
44. Ballantyne CM, Vasudevan AR. Cardiometabolic risk assessment: An approach to the prevention of cardiovascular disease and diabetes mellitus. Clinical Cornerstone 2005; 7(2/3): 7-17.
45. Vinik AI. The metabolic basis of atherogenic dyslipidemia. Clinical Cornerstone 2005; 7(2/3): 27-35.
46. Grundy SM. A constellation of complications: The metabolic syndrome. Clinical Cornerstone 2005; 7(2/3): 36-45.
47. Nesta RW. Managing cardiovascular risk in patients with metabolic syndrome. Clinical Cornerstone 2005; 7(2/3): 46-51.
48. Fonseca VA. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clinical Cornerstone 2005; 7(2/3): 61-72.
49. Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. NEJM 2005; 352(6): 539-48.
50. Dubey RK, Tofovic SP, Jackson EK. Cardiovascular pharmacology of estradiol metabolites. J of Pharm and Exp Therapeutics 2004; 308: 403-409.
51. Reuben DB, Palla SL, Reboussin BA, Crandall C, et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. The American Journal of Medicine 2006; 119: 167. el-167. e8.
52. Sader MA, Celermajer DS. Endothelial function, vascular reactivity and gender differences in the cardiovascular system. Cardiovascular Reasearch 2002; 53: 597-604.
53. Stork S, Baumann K, Von Schacky C, Angerer. The effect of 17 beta estradiol on MCP-1 serum levels in postmenopausal women. Cardiovascular Research 2002; 53: 643-649.
54. Quyyumi AA. Women and ischemic heart disease: Pathophysiologic implications from the WISE study and future research steps. J of the Am Coll of Cardio 2006; 47: 66S-71S.
55. Hu P, Greendale GA, Palla SL, Reboussin BA, et al. The effects on hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention trial. Atherosclerosis 2006; 185: 347-352. 5
56. Garcia-Moll X, Zouridakis E, Cole D, Kaski JC. C-reactive protein in patients with chronic stable angina: Differences in baseline serum concentration between women and men. European Heart Journal 2000; 21: 1598-1606.
57. Roussouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovascular Research 2002; 53: 550-557.
58. Shaw LJ, Merz NB, Pepine CJ, Reis SE, et al. Insights from the NHLBI-sponsored women’s ischemia syndrome evaluation (WISE) study. J of the Am Coll Cardio 2006; 47: 4S-29S.
59. Gierach GL, Johnson BD, Merz NB, Kelsey SF, et al. Hypertension, menopause, and coronary artery disease risk in the women’s ischemia syndrome evaluation (WISE) study. J of the Am Col Cardio 2006; 47: 50S-58S.
60. Laszlo B, Tanko Y, Bagger G. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2006; 111: 1883-1890. 6
1. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men. JAMA 2004; 292: 2243-2248.
2. de Bruin VM, Vieira MC, Rocha MN, Viana GS. Cortisol and dehydroepiandrosterone sulfate plasma levels and their relationship to aging, cognitive function, and dementia. Brain Cogn 2002; 50(2): 316-323.
3. Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects. Ann N Y Acad Sci 1995; 774: 128-142.
4. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78(6): 1360-1367. Erratum in: J Clin Endocrinol Metab 1995; 80(9): 2799.
5. Legrain S, Massien C, Lahlou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. Clin Endocrinol Metab 2000; 85(9): 3208-3217.
6. Labrie F, Diamond P, Cusan L, Gomez JL, Belander A, Candas B. Effect of 12-month dehydroepuandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997; 82(10): 3498-3505.
7. Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993; 169(6): 1536-1539.
8. Casson PR, Faquin LC, Stentz FB. Replacement of dehydroepiandrosterone enhances T-lynphocyte insulin binding in postmenopausal women. Fertility and Sterility 1995; 63(5): 1027-31.
9. Stomati M, Monteleone P, Casaros E, Quirici B, Puccetti S, Bernardi F, Genazzani AD, Rovati L, Luisi M, Genazzani AR. Six month oral dehydroespiandrosterone supplementation in early and late postmenopause. Dynecol Endocrinol 2000; 14: 342-63.
10. Arlt W, Callies F, Can Clijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine 1999; 341(14): 1013-1020.
11. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62: 154-162. 7
ESTROGENS: ESTRADIOL AND ESTRIOL
1. Lemon HM. Estriol prevention of mammary carcinoma induced by 7, 12 dimethylbenzanthracene and procarbazine. Cancer Res. 197535(5): 1341-1353.
2. Lemon HM, Kumar PF, Peterson C, Rodriguez-Sierra JF, Abbo KM. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer 1989; 63(9): 1685-1692.
3. Head KA. Estriol: Safety and efficacy. Altern Med Rev 1998; 3(2): 101-113.
4. Itoi H, Minakami H, Iwasaki R, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjufated estrogen on serum lipid profile in early menopausal women. Maturitas 2000; 36(3): 217- 222.
5. Koloszar S, Kovacs L. [Treatment of climacteric urogenital disorders with an estiol-containing ointment]. Orv Hetil 1995; 136(7): 343-345.
6. Sonni R, Bondi G, Travaglini S. [Presenile and senile vulvovaginitis. Topical hormonal treatment with estriol]. Minerva Ginecol 1991; 43(4): 177-179.
7. Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Zhonghua Yi Xue Za Zhi (Taipei). 1995; 55(5): 386-391.
8. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73(4): 606-612.
9. Giuliani A, Concin H, Wieser F, et al. [Hormone replacement therapy with a transdermal estradiol gel and oral micronized progesterone. Effect on menopausal symptoms and lipid metabolism]. Wien Klin Wochenschr 2000; 112(14): 629-633.
10. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999; 33(5): 1190-1194.
11. Molloy EJ, O”Neill AJ, et al. Sex-specific alterations in neutrophil spoptosis: the role of estradiol and progesterone. Blood 2003; 102(7): 2653-9.
12. Azcoitia I, Leonelli E, et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiology of Aging 2003; 24: 853-860.
13. Dalton K. The Premenstrual Syndrome and Progesterone Therapy
14. Santaro N, Rosenberg-Brown J, et al. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endo Metab 1996; 81: 1495-1501.
15. Polanczyk MJ, Carson BD, Subramanian S, et al. Cutting edge : Estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. The Journal of Immunology 2004; 173: 2227-2230.
16. Polanczyk M, Hopke C, Huan J, et al. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J of Neuroimmunology 2005.
17. Yue T, Wang X, Louden CS, et al. 2-Methoxyestradiol, and endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis : Possible role for stress-activated protein kinase signaling pathway and Fas expression. Molecular Pharmacology 1997; 51: 951-962.
18. Weiland N. Estradiol selectively regulates against binding sites on the N-Methyl-D-Aspartate receptor complex in the CA1 region of the hippocampus. Endocrinology 1992; 131: 662-668.
19. Van den Heuvel MW, Van Bragt AJ, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch, and an OC. Contraception 2005; 72: 168-174.
20. Richman S, Edusa V, Ahmed F, et al. Low-dose estrogen therapy for prevention of osteroporosis: working our way back to monotherapy. 8 Menopause 2006; 13(1): 148-155.
21. Cohen LS, Soares CN, Poitras JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: A preliminary report. Am J Psychiatry 2003; 160: 1519-1522.
22. Felson D, Cummings S. Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. ARTHRITIS & RHEUMATISM 2005; 52: 2594-2598.
23. Yue T, Wang X, Louden C, Gupta S, et al. 2-methoxyestradiol, and edogenous estrogen metabolite induces apoptosis in endothelial cells and inhibits angiogenesis: possible rold for stress activated protein kinase signaling pathway and fas expression. The American Society for Pharmacology and Experimental Therapeutics 1997; 51: 951-962.
24. Fotsis T, Zhang Y, Pepper M, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. NATURE 1994; 268: 237-239.
25. Sonni R, Bondi G, Travaglini S. [Presenile and senile vulvovaginitis. Topical hormonal treatment with estriol]. Minerva Ginecol 1991; 43(4): 177-179.
26. Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and bets signaling. IUBMB Life 2004 Aug: 56(8): 491-9.
27. Brandes JL. The influence of estrogen on migraine. JAMA 2006; 295(15): 1824-1830.
28. Canonico M, Oger E, Conard J, Meyers G, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estorgen administration. The ESTHER study. J of Thromb and Haemost 2006; 4(6): 1259-1265.
29. Whooley M, McCaffery J, et al. Association of serotonin transporter polymorphism (5-HTTLPR) with depression, perceived stress, and norepinephrine in patients with coronary disease: The Heart and Soul Study. Circulation 2007; 115(8). Parashar S, Rumsfeld JS, et al. Women, depression, and outcome of myocardial infarction. Circulation 2007; 115(8). 9
HORMONE REPLACEMENT THERAPY
1. Rossow, JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321- 33.
2. Anderson, GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701-12.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in perimenopausal, menopausal, and port menopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Reasearch group. JAMA 1998: 280; 605-613.
4. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the invidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 2003; 289: 2651-2662.
5. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-716.
6. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98(): 731-733.
7. Van Baal W, Kenemans P, Van der Mooren MJ, et al. Increased C-reactive protein levels durng short-term hormone replacement therapy in healthy postmenopausal women. Thrombosis and Haemostatsis 1999; 81(6): 925-8.
8. Rifai N, Buring JE, I-Min Lee, et al. Is C-Reactive protein specific for vascular disease in women? Annals of Internal Medicine 2002; 136(7): 529-533.
9. Duschek E, Neele SJ, et al. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. Blood Coagulation and Fibrinolysis 2004; 15(8): 649-655.
10. Abrahamsen B, Nommevie-Nielsen B, et al. Cytokines and bone loss in a 5 year longitudinal study hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1- receptor antagonist: the Danish Osteoporosis Prevention Study. J of Bone and Mineral Reasearch 2000; 15(8): 1545-54.
11. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291(14): 1701-1712.
12. Stark KD, Park EJ, Holub BJ. Fatty acid composition of serum phospholipids of Premenopausal and postmenopausal women receiving and not receiving hormone replacement therapy. Menopause 2003: 10(5): 448-55.
13. Col NF, Pauker SG. The discrepancy between observational studies and randomized trials of menopausal hormone therapy: did expectations shape experience? Ann Intern Med 2003; 139: 923-929.
14. Wilson PW, Garrison RJ, et al. Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50. The Framingham study. N Engl J Med 1985; 313: 1038-1043.
15. Edmunds E, Lundray M, Lip G. Hormone replacement therapy and intima-media thickness of the common carotid artery: The Rotterdam study. Stroke 2000; 31: 2266-i.
16. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288(7): 872-881.
17. Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. 10 JAMA 2004; 291(18): 2212-2220.
18. Stampfer MJ, Colditz GA, Willet WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. New England Journal of Medicine 1991; 325(11): 756-62.
19. Miyagawa K, Rosch J, et al. Medroxyprogesterone interfaces with ovarian steroid protection against coronary vasospasm. Nature Medicine 1997; 3(3): 324-327.
20. Fugh-Berman A, Scialli A. Gynecologists and estrogen: An affair of the heart. Perspectives in Biology and Medicine 2006; 49(1): 115-30.
21. Mandavilli A. Hormone in the hot seat. Nature Medicine 2006; 12(1): 8-9.
22. Barrett-Connor E, Grady D, Stefanick ML. The rise and fall of menopausal hormone therapy. Annu Rev Public Health 2005; 26: 1-26.
23. Barrett-Connor E. Hormones and heart disease in women: Where are we in 2005? Current Atherosclerosis Reports 2006; 8: 85-87.
24. Merz NB. Hormone therapy and cardiovascular risk: Why the focus on perimenopausal women? Advanced Studies in Medicine 2006; (6): 267-274.
25. Hsia J, Margolis KL, Eaton CB, et al. Prehypertension and cardiovascular disease risk in the Women’s Health Initiative. Circulation 2007; 115: 855-860.
26. Canonico M, Oger E, Plu-Bureau G, et al. The estrogen and thromboembolism risk (ESTHER) study. Hormone therapy and venous thromboembolism among postmenopausal women; impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840-845. 11
1. Majumdar SR, Almasi EA. Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA 2004; 292: 1983-1988.
2. Kassirer JP. Why should we swallow what these studies say? Advanced Studies in Medicine 2004; 4(8): 397-398.
3. Kravitz R, Epstein R, Feldman M, et al. Influence of patients’ requests for direct-to-consumer advertised antidepresants. JAMA 2005; 293(16): 1995-2002.
4. Stephenson K, Jones B, Stephenson D. The role of drug promotion in hormone replacement therapy prescribing in the United States. International Journal of Pharmaceutical Compounding 2006; 10(3): 174-181.
5. Abramson Overdosed America
6. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the
treatment of Non-ST-Segment elevation Acute coronary Syndrome. JAMA 2005; 294: 3108-3116.
7.Schmidt LM, Gotzsche PC. Of mites and med: references bias in narrative review articles: a systematic review. The Journal of Family Practice 2005; 54(4): 334-338.
8. Croasdale M. Innovative funding opens new residency slots. American Medical News 2006; 49(4): 1-4.
9. Welch Cline RJ, Young HN. Direct-to-consumer print ads for drugs: So they undermine the physician patient relationship? The Journal of Family Practice 2005; 54(12): 1049-1052.
10. Bower AD & Burkett GL. Family physicians and generic drugs: a study of recognition, information sources, prescribing attitudes, and practices. Journal of Family Practice 1987; 24: 612-616.
11. Caudill TS, Johnson MS, Rich EC, McKinney P. Physicians, pharmaceutical sales representatives and the cost of prescribing. Archives of Family Medicine 1996; 5: 201-206.
12. Chew LD, et al. A Physician Survey of the Effect of Drug Sample Availability on Physician’ Behavior. Journal of General Internal Medicine 2000; 15: 478-483.
13. Dieperink ME, Drogemuller L. Industry-sponsored grand rounds and prescribing behavior. Journal of the American Medicinal Association 2000; 285: 1443-1444.
14. Glenmullen J. Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants with Safe, Effective Alternatives 2000. New York: Simon and Schuster.
15. Lurie N, et al. Pharmaceutical representitives in academic medical centers: interaction with faculty and housestaff. Journal of General Internal Medicine 1990; 5: 240-243.
16. Orlowski JP & Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: There’s no such thing as a free lunch. Chest 1992; 102: 270-273.
17. O-Reilly KB. AMA opt-out program will keep prescribing data from drug reps. American Medical News 2006; 49(20): 1-2.
18. Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical promotion? Int J Health Services 1989; 19: 663-679.
19. PCPs More Influenced by Aggressive Marketing of Bipolar Drugs than Psychiatrists (2005) PR Newswire, Retrieved November 26, 2006 from www.proquest.com 12
1. Waddell BJ, O’Leary PC. Distribution and metabolism of topically applied progesterone in a rat model. Journal of Steroid Biochemistry & Molecular Biology 2002; 80: 449-455.
2. Stephenson K, Price C, Neuenschwander P, Kurdowska A, et al. Topical progesterone cream does not increase thrombotic and inflammatory factors in postmenopausal women. Blood 2004; 104(11): 415b.
3. Montplaisir J, Lorrain J, et al. Sleep in menopause : differential effects of two forms of hormone replacement therapy. Menopause: The Journal of the North American Menopause Society 2001; 8(1): 10- 16.
4. Plu-Beureau G, Le MG, et al. Percutaneous progesterone use and risk of breast cancer : results from a French cohort study of premenopausal women with benign breast disease. Cancer Detection and Prevention 19899; 23(4): 290-296.
5. Fitzpatrick LA, Pace C, et al. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women : a cross-sectional survey J of Women’s Health and Gender-based Medicine 2000; 9(4): 381-387.
6. Anasti JN, Leonetti HB, Wilson KJ. Topical progesterone cream has antiproliferative effect on estrogen stimulated endometrium. Obstet Gynecol 2001; 97( ): S10
7. Leonetti HB, Longo S, Anasti JN. Topical progesterone cream for vasomotor symptoms and post menopausal bone loss. Obstet Gyneol 1999; 94: 225-228.
8. Formby B, Wiley TS. Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse effects on Bcl-2 and p53. Ann Clin Lab Sci 1998; 28(6): 360-369.
9. Hermsmeyer RK, Rajesh G, Mishra DP, et al. Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. ArteriosclerThromb Vasc. Biol 2004; 24: 955-961.
10. Cermody BJ, Arora S, et al. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J Vasc Surg 2002; 36: 833-8.
11. Hermsmeyer K, Miyagawa K, et al. Reactivity-based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J Am Coll Card 1997; 29(3): 671-80.
12. Minshall RD, Stanczyk FZ, et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clinical Endo and Metab 1998; 83: 649-659.
13. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol 2001; 281: H1498-1507.
14. Rosano GMC, Webb CM, et al. Natural progesterone, but not Medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Card 2000; 36(7): 2154-9.
15. Hermsmeyer RIK, Mishra RG, Pavcnik D, Uchida B. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb VascBiol 2004; 24: 955-961.
16. Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. JEndocrinol 1998; 158(3): 401-407.
17. Brady BM, Anderson RA, et al. Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human mal. Clin Endo 2003; 58(4): 506-12.
18. Trainor BC, Bird IM, et al. Variation in aromatase activity in the medial preoptic area and plasma progesterone is associated with the onset of paternal behavior. 13 Neuroendocrinology 2003; 78(1): 36-44.
19. Azcoitia I, Leonelli E, et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in teh sciatic nerve of aged rats. Neurobiology of Aging 2003; 24(6): 853-60.
20. Bumke-Bogt C, Bahr V, Diederich S, et al. Expression of the progesterone receptor and progesterone metabolizing enzymes in the female and male human kidney. J of Endocrin 2002; 175(2): 349-64.
21. Maurer M, Trajanoski Z, et al. Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. Horm Metab Res 2001; 2(12): 691-5.
22. Mircioiu C, Perju A, et al. Pharmacokinetics of progesterone in postmenopausal women. Eur J of Drug Metab and Pharmacokinetics. 1998; 23: 397-401.
23. DeMasi Ma. Hormonally associated migrane. The Female Patient 2004; 29(7): 30-36.
24. Jette N, Morrell MJ. Sex-steroid hormones in women with epilepsy. The Female Patient 2004; 29(7): 23-29.
25. Donghai, et al. Progesterone inhibits human endometrial cancer cell growth and invasiveness: downregulation of cellular adhesion molecules through progesterone B receptors. Cancer Research 2002; 62: 881-886.
26. Gruber DM, Sator MO, et al. Progesterone and neurology. Gynecol Endocrin 1999; 13Suppl4: 41-5.
27. Sternberg WF, Chesler EJ, et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opioid analgesia in mice. Horm Behav 2004; 46(4): 46a7-473.
28. Unger J, Cady R, Farmer-Cady K. Migrane headaches, part 3: Hormonal factors. The Female Patient 2003; 28(7): 31-34.
29. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physio 2001; 281: H1498-41507.
30. Bergerson R, Demontigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. The Journal of Neuroscience 1996; 16(3): 1193-1202.
31. Ren K, Wei F, et al. Progesterone attenuates persistent inflammatory hyperalgesia in female rats: involvement of spinal NMDA receptor mechanisms. Brain Research 2000; 865: 272-277.
32. Rosano GMC, Webb CM, et al. Natural progesterone, but nor Medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise induced myocardial ischemia in postmenopausal women. J Am Coll Card 2000; 36(7): 2154-9.
33. Hermsmeyer RK, Mishra RG, Pavcnik D, Uchida B, et al. Prevention of coronary hyperactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004; 24: 955-961.
34. Azcoitia I, Leonelli E, et al. Progesterone and its derivatives dihydroprogesterone and tetrahydroprogesterone reduce myelin fiber morphological abnormalities and myelin fiber loss in the sciatic nerve of aged rats. Neurobiology of Aging 2003; 24: 853-860.
35. Minshall R, Pavcnik D, et al. Nongenomic vascodilator action of progesterone on primate coronary arteries. J Appl Physiol 2002; 92: 701-708.
36. Choi BC, Polgar K, et al. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Human Reproduction 2000. 15 Suppl 1: 46-59. 14
37. Minshall RD, Miyagawa K, Chadwick C, et al. In vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. The FASEB Journal 1998; 12: 1419-1429.
38. Stanczyk FZ, et al. Percutaneous administration of progesterone: blood levels and endometrial protaction. Menopause 2005; 12(2): 232-237.
39. Ferrell R, O’Connor K, Rodririguez G, et al. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age. Menopause 2005; 12: 567-577.
40. Burry K, Patton P, & Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. American Journal of Obstetric Gynecology 1999; 180: 1504-1511.
41. Bergeron R, Montigny C, and Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. The Journal of Neuroscience 1996; 16: 1193-1202.
42. Wilson ME. Premature elevation in serum insulin-like growth factor-I advances first ovulation in rhesus monkeys. Journal of Endocrinology 1998; 158: 247-257.
43. Gruber DM, Sator MO, Wieser F, Worda C & Huber JC. Progesterone and neurology. Gynecol Endocrinol 1999; 13: 41-45.
44. Rodriguez I, Kilborn MJ, Liu XX, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001; 285: 1322-1326.
45. Minshall RD, Pavcnik D, et al. Progesterone regulation of vascular thromboxane A2 receptors in rhesus monkeys. Am J Physiol Heart Circ Physiol 2001; 281: H1498-1507.
46. Hermsmeyer RIK, Mishra RG, Pavcnik D, Uchida B. Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone. Arterioscler Thromb Vasc Biol 2004; 24: 955-961.
47. Molloy EJ, O’Neill AJ, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003; 102(7): 2653-9.
48. Monjo M, Rodriguez AM, et al. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 2003; 144(11): 4923-30.
49. Unger J, Cady R, Farmer-Cady K. Migrane headaches, part 3: Hormonal factors. The Female Patient 2003; 28(7): 31-34.
50. Sternberg WF, Chesler EJ, et al. Acute progesterone can recruit sex-specific neurochemical mechanisms mediating swim stress-induced and kappa-opiod analgesia in mice. HormBehav 2004; 46(4): 467-473.
51. Kliman HB, Keefe CL. Route of progesterone affects rates of endometrial gland dyssynchrony in donor egg patients undergoing mock cycles. http://info.med.yale.edu/obgyn/kliman/infertility/abstracts/Prog.html accessed 2/23/05.
52. Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in-vitro embryotoxic TH1 cytokine production to trophoblast in women with recurrent pregnancy loss. Human Reproduction 2000; 15 Suppl 1: 46-59.
53. Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999; 180: 1504-11.
54. Martin VT, Behbehani M. Ovarian hormones and migrane headache: understanding mechanisms and pathogenesis. Headache 2006; 46(1): 2-23.
55. Xilouri M, Papazafiri P. Anti-apoptotic effects of allopregnanolone on P19 neurons. Eur J Neurosci 2006; 23(1): 43-54.
56. Dalton K. The Premenstrual Syndrome and Progesterone Therapy 2nd ed. London, England; Chicago, Ill: Year Book Medical Publishers; 1984. 15
57. Unger J, Cady R, Rermer-Cady K. Migraine headaches, part 3: hormonal factors. Female Patient 2003; 28: 31-34.
58. Vliet, E. An approach to preimenopausal migraine. Menopause Management 1995; Nov/Dec: 25-33.
59. Beynon HL, Garbett ND, Banres PJ. Severe premenstrual exacerbations of asthma: effect of intramuscular progesterone. Lancet 1988 Aug 13; 2(8607): 370-2.
60. Backstom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976 Oct: 54(4): 321-47.
61. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. Neurology 1986 Dec; 36(12): 1607-10.
62. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fert Steril 2000 Mar; 73: 516-521.
63. Miles RA, Paulson RJ, Lobo RA, Press MA, Dahmoush L, Sauer MB. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertility and Sterility 1995; 62: 485-490.
64. Taylor D. Perimenstrual symptoms and syndromes: Guidelines for symptom management and self care. Obstetrics and Gynecology 2005; 5(5): 228-241.
65. Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers.
Neuroendocrinology 1993 Oct; 58(4): 478-84.
66. Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Comrp Ther 1998 Jun-Jul; 24(6-7): 336-9.
67. Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Stero; 2003; 79(1): 221-222. 16
1. Gozansky W.S, Lynn J.S, Laudenslager M.L. Kohrt W.M. Salivary cortisol determined by enzyme
immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic – pituitary – adrenal axis activity. Clinical Endocrinology. 2005; 63:336-341
2. Stpehenson, K., Tha Salivary Hormone Assessment in the Clinical Evaluation of the Female Patient. InternationalJ of Pharmaceutical Compounding.2004;8(6):427-435.
3. Riad-Fahmy D, Read GF, Walker RF. Salivary steroid assay for assessing variation in endocrine activity. J Steroid Biochem 1983; 19:265-272.
4. Read GF, Walker RF, Wilson DW, Griffith K. Steroid analysis in saliva for the assessment of endocrine function. Ann NY Acad Sci 1193; 260-274.
5. Finn MM, Gosling JP, Tallon DF, Baynes S, Meehan FP, Fotrell PF. The frequency of salivary progesterone sampling and the dx of luteal phase insufficiency. Gynecol Endocrinol 1193; 6: 128-134. 6. Lu Y, Bentley GR, Gann PH, Hodges KR, Chatterton RT. Salivary estradiol and progesterone levels in conception and nonconception cycles in women: evaluation of a new assay for salivary estradiol. Fertil Steril 1999; 71: 863-868.
7. Lu YC, Chatterton RT, Vogelsong KM, May LK. Direct redioimmunioassay of progesterone in saliva. J Immunoassay 1997; 18: 149-163.
8. Sumiala S, Tuominen J, Huhtaniemi I, Maenpaa J. Salivary progesterone concentration after tubal sterilization. Obstet Gynecol 1996; 88: 792-796.
9. Campbell BC, Ellison PT. Menstrual variation in salivary testosterone among regulatly cycling women. Horm Res 1993; 37: 132-136.
10. Harris B, Lovett L, Newcombe RG, Read GF, Walker R, Riad-Fahmy D. Maternity blues and major endocrine changes: Cardiff puerperal mood and hormone study. BMJ 1994 Apr; 308: 949-953.
11. Lo MS, Ng ML, Azmy BS, Khalid BA. Clinical application of salivary cortisol measurement. Sing Med J 1992; 33: 170.
12. Dabbs JM. Salivary testosterone measurement: collecting, storing, and mailing saliva samples. Phys Behav 1991; 49: 815-817.
13. Dabbs JM, Salivary testosterone measurements; reliability across hours, days, and weeks Phys Behav
1990; 48: 83-86.
14. Dabbs JM, Campbell BC, Gladne BA, Midgley AR, Navarro MA, Read GF, Susman EJ, Sumkels LM, Worturer CM. Reliability of salivary testosterone measurement; a multicenter evaluation. Clin Chem
1995; 41: 1581-1584.
15. Petsos P, Reatcliffe WA, Heath PF, Anderson DC. Coparisons of blood spot, salivary and serum progesterone assays in the normal menstrual cycle. Clin Endocrin 1986: 24; 31-38.
16. Read GF, Walker RF, Wilson DW, Griffith K. Steroid analysis in saliva for the assessment of endocrine function Ann NY Acad Sci 1993; 260-274.
17. Riad-Fahmy D, Read GF, Walker RF. Salivary steroid assays for assessing variation in endocrine activity. J Steroid Biochem 1983; 19: 265-272.
18. Lipson SF, Ellison PT. Development of protocols for the application of salivary steroid analysis to field conditions. AM J Human Biol 1989; 1: 249-255.
19. Spearoff L, Glass R, Kase N. Clinical Gynecologic Endocrinology and Infertility, Williams and Wilkins, Baltimore, Maryland.
20. Koefoed P, Brahm J. The permeability of the human red cell membrane to steroid sex hormones. Biochim Biophys Acto 1994; 1195: 55-62.
21. Hirmamatsu R, Nisula B. Uptake of erythrocyte associated component of blood testosterone and corticosterone to rat brain. J Steroid Biochem Molec Biol 1991; 38: 383-387. 17
22. Sannika E, Terho P, Suominen J, Santli R. Testosterone concentrations in human seminal plasma and saliva and its correlation with non-protein-bound and total testosterone levels in serum. Int J Andrology 1983; 6: 319-330.
23. McCracken J, Schramm W, Einer-Jenson W. The structure of steroids and their diffusion through blood vessel walls in a counter current system. Steroids 1984; 43: 293-303.
24. Krzymowski T, et.al. Steroid transfer from the ovarian vein to the ovarian astery in the sow. J Reprod. Fertil 1982; 65: 451-456.
25. Vining R, McGinly R, Symons R. Hormones in saliva; mode of entry and consequent implications for clinical interpretation. Clin Chem 1983; 29: 1752-1756.
26. Swinkels LM, Ross HA, Smals AG, Benraad TJ. Concentration of total and free dehydroepiandrosterone in plasma and dehydroepiandrosterone in saliva of normal and hirsuite women under basal conditions and during administration of dexamthathesone and corticotrophin. Clin Chem 1990; 16: 2042-2046.
27. Vinign R, McGinly R, Maksvytis J, Ho K. Salivary cortisol: a better measure of adrenal cortical function than serum cortisol. Ann Clin Biochem 1983; 20: 329-335.
28. Devenuto F, Ligon DF, Friedreichsen DH, Wilson HL. Human erythrocyte membrane. Uptake of progesterone and chemical alterations. Biochem Biophys Acta 1969; 193: 36-47.
29. ZRT Laboratories, Comparative pricing of saliva vs. blood serum hormone testing, Beaverton, Oregon, 2003. 18
STRESS IN WOMEN
1. Elenkov IJ, Webster EL, Torpy DJ, et al. Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronis effects. Annals of NY Acad of Sciences 1999; 876: 1-13.
2. Elenkov IJ. Systemic stress-induced Th2 shift and its clinical implications. Interna Revi of Neurobiology 2002; 52: 163-186.
3. Papanicolaou DA, Wilder RL, et al. The pathophysiologic roles of Interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
4. Elenkov IJ, Chrousos GP. Stress, cytokine patterns and susceptibility to disease. Bailliere’s Clinical Endocri and Metabl 1999; 13: 583-595.
5. Elenkov IJ, Webster EL, Torpy DJ, et al. Stress, corticotrophin-releasing hormone, glucocorticoids, and the immune/inflammatory response: Acute and chronic effects. Ann NY Acad Sci 1999; 876: 1-13.
6. Kunz-Ebrecht SR, Mohamed-Ali V, Fledman PJ, et al. Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. Brain Behav Immun 2003; 17(5): 373-383.
7. Black PH. The inflammatory reponse is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003; 17(5): 350-364.
8. Sephton S, Spiegel D. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 2003; 17(5): 321-328.
9. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res 2002; 52(1): 1-23.
10. Hawkley LC, Burleson MH, et al. Cardiovascular and endocrine reactivity in older females: intertask consistency. Psychophysiology 2001; 38: 863-72.
11. Heim C, Newport DJ, et al. The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: a multiple regression analysis. Depression and Anxiety 2002; 15: 117-25.
12. Selye H. The Stress of Life. Revised ed. New York, NY: McGraw Hill; 1976.
13. Elenkov IJ. Systematic stress-induced Th2 shift and its clinical implications. Int Rev Neurobiol 2002; 52: 163-186.
14. Elenkov IJ, Webster EL, Torpy DJ, et al. Stress, corticotrophin-releasing hormone, glucocorticoids, and the immune/inflammatory response: Acute and chronic effects. Ann NY Acad Sci 1999; 876: 1-13.
15. Kunz-Ebrecht SR, Mohamed-Ali V, Feldman PJ, et al. Cortisol responses to mild psychological stress are inversely associated with proinflammatory cytokines. Brain Behav Immun 2003; 17(5): 373-383.
16. Hiwm C, Newport DJ, et al. The rols of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women; a multiple regression analysis. Depression and Anxiety 2002; 15: 117-25.
17. Leucken LJ, Suarez EC, et al. Stress in employed women: impact of marital status and children at home on neurohormone output and home strain. Psychosom Med 1997; 59: 352-359.
18. Padgett DA, Glaser R. How stress influences the immune response. Trends in Immunol 2003; 24: 444-48.
19. Epel E, Blackburn E, Lin J, et al. Accelerated telomere shortening in response to life stress. PNASA 2004; 101: 17312-17315.
20. Beer J, Beer J. Burnout and stress, depression and self-esteem of teachers. Psychol Rep 1992; 71(3 Pt 2): 1331-1336.
21. Segerstrom SC, Miller GE. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry. Psych Bull 2004; 130(4): 601-630.
22. Baum A, cohen L, Hall M. Control and intrusive memories as possible determinants of chronic stress. Psychosom Med 1993; 55(3): 274-286. 19
23. Dantzer R. Cytokine-induced sickness behavior: A neuroimmune response to activation of innate immunity. Eur J Pharmacol 2004; 500: 399-411.
24. Janice K. Kiecolt-Glaser, PhD; Timothy J. Loving, PhD; Jeffrey R. Stowell, PhD; Williams B. Malarkey, MD; Stanley Lemeshow, PhD; Stephanie L. Dickinson, MAS; Ronald Glaser, PhD. Hostile marital interactions, proinflammatory cytokine production, and would healing. Arch Gen Psychiatry 2005; 62: 1377-1384.
25. Gozansky WS, Lynn JS, Laudenslager ML, et al. Salivary cortisol determined by enzyme immunoassay is preferable to serum total cortisol for assessment of dynamic hypothalamic-pituitary-adrenal axis activity. Clinical Endocrinology 2005; 63: 336-341.
26. Krause N. Shaw BA, Cairney J. A descriptive epidemiology of lifetime trauma and the physical health status of older adults. Psychol Aging 2004; 19(4): 637-48.
27. Krause N. Exploring age differences in the stress-buffering function of social support. Psychol Aging 2005; 20(4): 714-7.
28. Everly GS. The development of a stress scale to assess behavioral health factors; The Everly Stress and Symptom Inventory Advances in Health Education 1989; 2: 71-86.
29. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. PNAS 2004; 101(49): 17312-17315.
30. Luecken LJ, Rodiriguez AP, Appelhans BM. Cardiovascular stress responses in young adulthood associated with family-of-origin relationship experiences. Psychosomatic Medicine 2005; 67: 513-521.
31. Olson MB, Krantz DS, Kelsey SF, et al. Hostility scores are associated with increased risk of cardiovascular events in women undergoing coronary angiography: A report from the NHLBI-Sponsored Women’s Ischemic Syndrome Evaluation (WISE) Study. Psychosomatic Medicine 2005; 67: 546-552.
32. Eskandari F, Mistry S, Martinez PE, et al. Younger, Premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: Implications for greater cardiovascular risk. The POWER Study. Metabolism Clinical and Experimental 2005; 54: 918-924.
33. Kiecolt-Glaser JK, Loving TJ, Stowell JR, Malarkey WB, et al. Hostile marital interactions, proinflammatory cytokine production and wound healing. Archives of -General Psychiatry 2005; 62(12): 1377-1384.
34. Pruessner JC, Hellhammer DH, Kirschbaum C. Burnout, perceived stress and cortisol response to awakening. Psychosom Med 1999; 61: 197-204.
35. Stones A, Groome D, Perry D, Hucklebridge F, Evans P. The effect of stress on salivary cortisol in panic disorder patients. J Affect Disorders 1999; 52: 197-201.
36. Vedhara K, Hyde J, Gilchrist ID, Tytherleigh M, Plummer S. Acute stress, memory, attention, and cortisol. Psychoneuroendocrin 2000; 25: 535-549.
37. Scott L, Salahuddin F, Cooney J, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression, and in health. J Affect Disord 1999; 54: 129-137.
38. Kudielka BM, Schmidt-Reinwald AK, Hellhammer DH, Kirschbaum C. Psychological and endocrine responses to psychological stress and dexamethasone/corticotrophin-releasing hormone in healthy postmenopausal women and young controls: the impact of age and a two-week estradiol treatment. Neuroendocrinol 1999; 70: 422-430.
39. Heim C, Ehlert U, Hanker JP, Hellhammer DH. Abuse-related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain. Psychosom Med 1998; 60: 309-318.
40. Yehuda R, Golier J.A., & Kaufman S. Circadian rhythm of salivary cortisol in holocaust survivors with and without PTSD. American Journal of Psychiatr 2005; 162: 998-1000. 20
41. Winter H & Irle E. Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. The American Journal of Psychiatry 2004; 161(12): 2194-2200.
42. Van der Kolk, B. The psychobiology of posttraumatic stress disorder. Journal of Clinical Psychiatr 1997; 58(9): 16-24.
43. Sapolsky, M. Social status and health in humans and other animals. Annual Review of Anthropology 2004; 33: 393-419.
44. Griffin M.G., Resick P.A., & Yehuda R. Enhanced cortisol suppression following dexamethasone administration in domestic violence survivors. American Journal of Psychiatry 2005; 162: 1192-1199.
45. Karten YJG, Olariu A & Cameron HA. Stress in early life inhibits neurogenesis in adulthood. Trends in Neuroscience 2005; 28(4): 171.
46. Lee AL, Ogle WO & Sapolsky RM. Stress and depression: Possible links to neuron death in the hippocampus. Bipolar Disorders 2002; 4(2): 117-128.
47. Lupien SJ, De Leon M, De Santi S, Convit A, Tarshish C, Nair NPV, Thakur M, McEwen BS, Hauger RL & Meaney MJ. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience 1998; 1(12): 69-73.
48. Newcomer J, Selke G, Melson A, Hershey T, Craft S, Richards K & Alderson A. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Archives of General Psychiatry 1999; 56: 527-533.
49. Chrousos GP & Gold PA. A healthy body in healthy mind – and vice versa – the damaging power of “uncontrollable” stress. The Journal of Clinical Endocrinology & Metabolism 1998; 83(6): 1842-1845.
50. Sherline Y, Gado M, Kraemer H (2003). Untreated depression and hippocampal volume loss. American Journal of Psychiatry 160: 1516.
51. Sherline Y, Sanghavi M, Mintun M & Gado M. Depression duration but nor age predicts hippocampal volume loss in medical healthy women with recurrent major depression. Journal of Neuroscience 1999; 19: 5034-5041.
52. Medical Letter on the CDC & FDA (2005, June 5). Alzheimer disease; up-regulation of glutathione protects neurons against A-beta toxicity. Alanta: 13.
53. Newcomer J, Selke G, Melson A, Hershey T, Craft S, Richards K & Alderson A. Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Archives of General Psychiatry 1999; 56: 527-533.
54. Karten YJG, Olariu A & Cameron HA. Stress in early life inhibits neurogenesis in adulthood. Trends in Neuroscience 2005; 28(4): 171.
55. Lerner JS, Gonzalez RM, Dahl RE, et al. Facial expressions of emotion reveal neuroendocrine and cardiovascular stress responses. Biol Psychiatr 2005; 58: 743-750.
56. Dedert EA, Studta JL, Weissbecher I, et al. Religiosity may help preserve the cortisol rhythm in women with stress-related illness. Int J Psych in Med 2004; 34(1): 61-77.
57. Camacho A, Dimsdale JE. Platelets and psychiatry: lessons learned from old and new studies. 58.
Bliel ME, McCaffery JM, et al. Anger-related personality traits and carotid artery atherosclerosis in untreated hypertensive men.
59. Lovallo WR, Gerin W. Psychophysiological reactivity: mechanisms and pathways to cardiovascular disease.
60. Vrijkotte TG, Van Doornen SJP. Work stress and metabolic and hemostatic risk factors. 61. Vrijkotte TG, Van Doornen LJP, et al. Overcommitment to work is associated with changes in cardic sympathetic regulation. 21
1. Bachmann G, Bancroft J, Braustein G, et al. Female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77(4): 660-665.
2. Notelovitz M. Hot flashes and androgens: A biological rationale for clinical practice. Mayo Clin Proc 2004; 79(4 Suppl): S8-S13.
3. Burger HG, Dudley EC, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000; 85(8): 2832-2838.
4. Ehrenreish H, Halaris A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res 1999; 33(5): 379-387.
5. Apperloo MJ, Van Der Stege JG, Hoek A, et al. In the mood for sex: The value of andorgens. J Sex Marital Ther 2003; 29(2): 87-102.
6. Jensen MD. Andorgen effect on body composition and fat metabolism. Mayo Clin Proc 2000; 75(Suppl): S65-S68.
7. Sowers MF, Beebe JL, McConnell D, et al. Testosterone concentrations in women aged 25-50 years: Associations with lifestyle, body composition, and ovarian status. Am J Epidemiol 2001; 153: 256-264.
8. Almeida OP. Sex playing with the mind. Effects of oestrogen and testosterone on mood and cognition. Arch Neuropsysch 1999; 57(3A): 701-706.
9. Fink G, Sumner BE, McQueen JK, et al. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol 1998; 25(10): 764-775.
10. Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenidione and dihydrotestosterone concentrations and elevated in female patients with major depression. Psychoneuroendocrinology 2000 25(8): 765-771.
11. Davis SR, Tran J. Testosterone influences libido and well being in women. Trends Endocrinol Metab 2001; 2(1): 33-37.
12. Rohr UD. The impact of testosterone imbalance on depression and women’s health. Maturitas 2002; 41(Suppl): S25-S46.
13. Bachmann G, Bancroft J, Braunstein G, et al. female androgen insufficiency: The Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77(4): 660-665.
14. Notelovitz M. Hot flashes and androgens: A biological rationally for clinical practice. Mayo Clin Proc 2004; 79($ Suppl): S8-S13.
15. Moller J, Einfeldt H. Testosterone Treatment of Cardiovascular Diseases. Berlin: Springer Verlag; 1984.
16. Sowers MF, Beebe JL, McConnell D, Randolph J, Jannausch M. Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composisiton, and ovarian status. Am J Epidemiol. 2001; 153(3): 256-264.
17. Maurer M, Trajanoski Z, Frey G, et al. Differential gene expression profile of glucocorticoids, testosterone, and dehydroepiandrosterone in human cells. Horm Metab Res. 2001; 33(12): 691-695.
18. Monjo M, Rodriguez AM, et al. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 2003; 144(11): 4923-30.
19. Rohr UD. The impact of testosterone imbalance on depression and women’s health. Maturitas 2002; 41(Suppl): S25-S46. 22
20. Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenidione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000; 25(8): 765-771.
21. Swoers MF, Beebe JL, McConnell D, et al. Testosterone concentrations in women aged 25-50 years: Associations with lifestyle, body composition, and ovarian status. Am J Epidemiol 2001; 153: 256-264.
22. Monjo M, Ordriguez AM, et al. Direct effects of testosterone, 17 beta-estradiol, and progesterone on adrenergic regulation in cultured brown adipocytes: potential mechanism for gender-dependent thermogenesis. Endocrinology 2003; 144(11): 4923-30.
23. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and –independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab. 2001; 86(1): 158-161.
24. English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves agina threshold in men with chronic stable angina. Circulation 2000; 120: 1906-1911.
25. Wabitsch M, Hauner H, Heinze E, Bockmann A, Benz R. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab. 1995 Dec; 80(12): 3469-75.
26. Donato GB, Fuchs SC, Oppermann K. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006; 13(2): 280-285.
27. Sari M, Van Anders MA, Hampson E. Waist-to-hip ratio is positively associated with bioavailable testosterone but negatively associated with sexual desire in healthy premenopausal women. Psychosomatic Medicine 2005; 67: 246-250.
28. Janssen I, Powell LH, et al. Development of the metabolic syndrome through menopause: The Study of Women’s Health Across the Nation (SWAN). Circulation 2007; 115(8). 23